NEW YORK, NY--(Marketwire - May 9, 2012) - In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Complete Genomics, Inc. (NASDAQ: [ GNOM ]) and Neostem Inc. (NYSE Amex: [ NBS ]).

Access to the full company reports can be found at:

[ www.FiveStarEquities.com/GNOM ]

[ www.FiveStarEquities.com/NBS ]

The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system," BIO President and CEO Jim Greenwood stated in a press release. "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.FiveStarEquities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. Complete Genomics ended the first quarter 2012 with $63.1 million in cash, cash equivalents and short-term investments and $0.5 million in restricted cash. The company's backlog as of March 31, 2012 was approximately 5,700 genomes, including about 1,000 genomes booked in the first quarter, representing an aggregate revenue potential of approximately $27 million.

NeoStem is an international biopharmaceutical company with global research and development capabilities. In the United States the Company is a provider of adult stem cell collection, processing and storage services enabling healthy individuals to donate and store their stem cells for personal therapeutic use. Similar to the banking of cord blood, pre-donating cells at a younger age helps to ensure a supply of one's own stem cells should they be needed for future medical treatment.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

[ www.FiveStarEquities.com/disclaimer ]